Vinaxanthone, a new FabI inhibitor from Penicillium sp

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 5, 2009, Pages 949-953

  Zheng, Chang Ji ^a   Sohn, Mi Jin ^a   Kim, Won Gon ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Antibacterial; Enoyl ACP reductase; Fatty acid synthesis; Staphylococcus aureus; Target validation

Indexed keywords

ANTIBIOTIC AGENT; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADPH); ENZYME INHIBITOR; UNCLASSIFIED DRUG; VINAXANTHONE;

ARTICLE; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; FATTY ACID SYNTHESIS; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; GROWTH INHIBITION; IC 50; MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PENICILLIN RESISTANCE; PENICILLIUM; PROTEIN SYNTHESIS; STRUCTURE ANALYSIS; WILD TYPE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MOLECULAR STRUCTURE; PENICILLIUM; STAPHYLOCOCCUS AUREUS; XANTHONES;

EID: 64649097918     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp058     Document Type: Article

References (26)

1. Levy SB, Marshall B. Antibacterial resistance worldwide: Causes, challenges and responses. Nat Med 2004; 10: 122-9.
2. Pfeltz RF, Wilkinson BJ. The escalating challenge of vancomycin resistance in Staphylococcus aureus. Curr Drug Targets Infect Disord 2004; 4: 273-94.
3. Miesel L, Greene J, Black TA. Genetic strategies for antibacterial drug discovery. Nat Rev Genet 2003; 4: 442-56.
4. Campbell JW, Cronan JE. Bacterial fatty acid biosynthesis: Targets for antibacterial drug discovery. Annu Rev Microbiol 2001; 55: 305-32.
5. Heath RJ, Rock CO. Fatty acid biosynthesis as a target for novel antibacterials. Curr Opin Investig Drugs 2004; 5: 146-53.
6. Zhang YM, White SW, Rock CO. Inhibiting bacterial fatty acid synthesis. J Biol Chem 2006; 281: 17541-4.
7. McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. Nature 1998; 394: 531-2.
8. Heath RJ, Rubin JR, Holland DR et al. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J Biol Chem 1999; 274: 11110-4.
9. Singh MP, Greenstein M. Antibacterial leads from microbial natural products discovery. Curr Opin Drug Discov Devel 2000; 3: 167-76.
10. Zheng CJ, Sohn MJ, Lee S et al. Cephalochromin, a FabI-directed antibacterial of microbial origin. Biochem Biophys Res Commun 2007; 362: 1107-12.
11. Wang J, Soisson SM, Young K et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006; 441: 358-61.
12. Kumagai K, Hosotani N, Kikuchi K et al. Xanthofulvin, a novel semaphoring inhibitor produced by a strain of Penicillium. J Antibiot 2003; 56: 610-6.
13. Zheng CJ, Sohn MJ, Kim WG. Atromentin and leucomelone, the first inhibitors specific to enoyl-ACP reductase (FabK) of Streptococcus pneumoniae. J Antibiot 2006; 59: 808-12.
14. Slater-Radosti C, Van Aller G, Greenwood R et al. Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus. J Antimicrob Chemother 2001; 48: 1-6.
15. Aoki M, Itezono Y, Shirai H et al. Structure of a novel phospholipase C inhibitor, vinaxanthone (Ro 09-1450), produced by Penicillium vinaceum. Tetrahedron Lett 1991; 56: 610-6.
16. Gammon G, Chandler G, Depledge C et al. A fungal metabolite which inhibits the interaction of CD4 with major histocompatibility complex-encoded class II molecules. Eur J Immunol 1994; 24: 991-8.
17. Sivaraman S, Zwahlen J, Bell AF et al. Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli by triclosan: Kinetic analysis of mutant FabIs. Biochemistry 2003; 42: 4406-13.
18. Ward WH, Hoidgate GA, Rowsell S. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 1999; 38: 12514-25.
19. Zhang YM, Rock CO. Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase. J Biol Chem 2004; 279 30994-1001.
20. Heerding DA, Chan G, DeWolf WE et al. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier reductase (FabI). Bioorg Med Chem Lett 2001; 11 2061-5.
21. Miller WH, Seefeld MA, Newlander KA et al. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J Med Chem 2002; 45: 3246-56.
22. Payne DJ, Miller WH, Berry V et al. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob Agents Chemother 2002; 46: 3118-2.
23. Seefeld MA, Miller WH, Newlander KA et al. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J Med Chem 2003; 46: 1627-35.
24. Ling LL, Xian J, Ali S et al. Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase. Antimicrob Agents Chemother 2004; 48: 1541-7.
25. Tasdemir D, Lack G, Brun R et al. Inhibition of Plasmodium falciparum fatty acid biosynthesis: Evaluation of FabG, FabZ, and FabI and drug targets for flavonoids. J Med Chem 2006; 49: 3345-53.
26. Sohn MJ, Zheng CJ, Kim WG. Macrolactin S, a new antibacterial agent with FabG-inhibitory activity from Bacillus sp. AT28. J Antibiot 2008; 61: 687-91.